Russia's Enteromix Cancer Vaccine Shows 100% Success, Awaits Final Approval
Advertisement
Russia's experimental mRNA-based cancer vaccine Enteromix has demonstrated 100% efficacy and safety in clinical trials, raising hopes for a breakthrough in the global fight against cancer. Developed using similar technology as COVID-19 vaccines, Enteromix works by training the immune system to recognize and eliminate cancer cells without serious side effects.
The announcement was made by the Federal Medical and Biological Agency (FMBA) of Russia, with its head Veronika Skvortsova confirming that the vaccine had successfully completed preclinical studies and was now ready for clinical use.
For more details, check out the full story on the link below:
Russia's Enteromix Cancer Vaccine Shows 100% Success in Trial, Awaits Final Nod for Public Use
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.